Internal Medicine, Endocrinology, Diabetes, & Metabolism · Huntsville, AL
NPI
1043634991
Since 2014
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
201 Sivley Rd SW Ste 440
Huntsville, AL, 35801
Phone (256) 265-0780
Groups this clinician bills Medicare through
Medicare paid, 2024
$89K
1,615 services
Medicare patients, 2024
526
Average age 71
Drug cost, 2024
$4.1M
5,931 prescriptions
Company payments, 2025
$1,071
From 16 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Malapuram Vasudha Reddy was code 99214 (office e&m - established), 842 times for 406 patients. In total Malapuram Vasudha Reddy billed 1,615 services in 12 codes, and Medicare paid $89K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-07-31.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 842 | 406 | $62.45 | $53K |
| 95251 Test - Miscellaneous | Facility | 363 | 167 | $22.79 | $8,272 |
| 99232 Hospital E&M - Subsequent | Facility | 207 | 63 | $58.37 | $12K |
| 99204 Office E&M - New | Facility | 97 | 97 | $87.93 | $8,529 |
| 99222 Hospital E&M - Initial | Facility | 43 | 42 | $89.71 | $3,858 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 24 | 24 | $8.77 | $210 |
| 99205 Office E&M - New | Facility | 23 | 23 | $122.02 | $2,807 |
By year: 2022 $79K for 1,258 services; 2023 $93K for 1,537 services; 2024 $89K for 1,615 services.
Medicare prescription drug claims, 2024
In 2024, the drug Malapuram Vasudha Reddy prescribed most often to Medicare patients was Mounjaro (Tirzepatide), with 574 prescriptions and refills. In total Malapuram Vasudha Reddy wrote 5,931 Medicare prescriptions that cost $4.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Mounjaro Tirzepatide | 574 | 817 | 140 | $849K |
| Ozempic Semaglutide | 565 | 920 | 141 | $866K |
| Jardiance Empagliflozin | 499 | 1,105 | 145 | $619K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 400 | 834 | 143 | $82K |
| Levothyroxine Sodium Generic | 325 | 910 | 105 | $3,966 |
| Tresiba Flextouch U-100 Insulin Degludec | 287 | 628 | 91 | $361K |
| Metformin Hcl Generic | 261 | 732 | 89 | $2,723 |
| Trulicity Dulaglutide | 210 | 316 | 63 | $292K |
| Pioglitazone Hcl Generic | 184 | 502 | 53 | $3,907 |
| Glipizide Generic | 180 | 456 | 71 | $2,225 |
| Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 | 135 | 265 | 38 | $213K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 120 | 316 | 62 | $12K |
| Glipizide Er Glipizide | 105 | 300 | 40 | $2,347 |
| Metformin Hcl Er Metformin Hcl | 104 | 255 | 39 | $1,293 |
| Humalog Insulin Lispro | 94 | 199 | 34 | $38K |
Brand drugs: 3,596 claims; generic drugs: 1,672 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Malapuram Vasudha Reddy $1,071 ($1,071 in general payments such as food, travel and fees) from 16 companies. The largest payer was Insulet Corporation with $246.
| Company | Payments | Amount |
|---|---|---|
| Insulet Corporation PODD | 18 | $246 |
| Medtronic, Inc. MDT | 12 | $158 |
| Novo Nordisk Inc NVO | 15 | $154 |
| Dexcom, Inc. DXCM | 9 | $137 |
| Abbott Laboratories ABT | 4 | $84.55 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 3 | $61.84 |
| Xeris Pharmaceuticals, Inc. | 2 | $46.29 |
| Amgen Inc. AMGN | 2 | $38.5 |
| Sanofi-Aventis U.S. LLC SNY | 2 | $31.18 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $19.58 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.